Tuesday, June 29, 2021 Daily Archives

Process Intensification: Ways to Achieve Extreme Biologics Volumetric Productivity

This webcast features: Xiao Pan, Director of Process R&D, GenScript ProBio The trend of biologics titer increase brings significant cost reduction. Process intensification needs to be introduced and applied to improve the titer performance and lower the COGS. Besides fed batch, GenScript ProBio has developed process intensification solutions including high-density inoculation and intensified perfusion. Through this webinar, you will learn the following information: The scope and trend of process intensification Intensified perfusion development roadmap Case study of process intensification Just…

Quantoom and eTheRNA to build RNA production system

Quantoom and eTheRNA have partnered to build RNA technology, which aims to produce affordable RNA-based therapies for distribution in 2023.   Under the terms of the agreement, eTheRNA will provide Quantoom Biosciences, a Univercells company, with all required material and data for the development of an RNA production system (RPS) in Belgium. The system aims to reduce cost through optimized processes and automation. Once the RPS is developed, Quantoom will be responsible for its global commercialization and both firms expect…

Fujifilm pumps another $850m into its CDMO business

Fujifilm Diosynth Biotechnologies (FDB) will double cell culture production for recombinant vaccines in the US and increase gene therapy production in the UK ten-fold as part of its latest investment plans. The ¥90 billion ($850 million) expansion will increase capacity across a range of modalities on both sides of the Atlantic. As well as doubling cell culture production for recombinant vaccines in the US, the firm will grow capacity at its Teeside, UK site to increase gene therapy production ten-fold,…

Sanofi doubles down on mRNA vaccines with $475m annual booster shot

‘The mRNA story is just beginning’ says Sanofi as it builds on its partnership with Translate Bio by launching dedicated vaccine R&D centers in Massachusetts and France. The French pharma giant announced plans today to invest €400 million ($475 million) annually into what it describes as its ‘mRNA Center of Excellence’ to accelerate R&D of next-generation vaccines. The ‘Center’ will in fact be spread across two of Sanofi’s locations, Cambridge (Boston) in Massachusetts and in Marcy L’Etoile (near Lyon), France,…